Compare Immunovant Inc. Common Stock (IMVT) vs Nasdaq100 ETF (QQQ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Immunovant Inc. Common Stock vs Nasdaq100 ETF — how do they compare? Immunovant Inc. Common Stock trades at $30.27 (market cap $6.25B), while Nasdaq100 ETF trades at $753.73 (market cap $506.92B). The key difference: Nasdaq100 ETF is far larger — about 81.1× Immunovant Inc. Common Stock's market cap, and Nasdaq100 ETF is trading nearer its 52-week high, Immunovant Inc. Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Immunovant Inc. Common Stock for 0 Days and Nasdaq100 ETF for 162 Days on average.
| IMVT | QQQ | |
|---|---|---|
Market Cap | $6.25B | $506.92B |
Volume | 1,755,411 | 48,326,518 |
Sector | Health | — |
52-Week High | $44.96 | $759.66 |
52-Week Low | $17.03 | $558.34 |
Typical Hold Time | 0 Days | 162 Days |
Enterprise Value | $5.35B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
QQQ trades at $757.73, down 0.25% on the day, with a bullish technical signal from moving averages but bearish oscillators. The ETF shows mixed analyst sentiment with a 50% buy and 50% sell consensus. Recent news highlights comparisons with lower-fee alternatives like QQQM and VOO, while broader market concerns about AI valuations and interest rate impacts create headwinds.
The outlook for QQQ remains tied to technology sector performance and AI-driven growth, though elevated valuations and concentration risk warrant caution. Near-term support lies at $754, with resistance at $760. Investors face balancing growth potential against fee differentials and market volatility risks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Immunovant Inc. Common Stock
Immunovant is a clinical-stage immunology company developing therapies for autoimmune diseases. Its pipeline includes anti-FcRn antibody candidates designed for subcutaneous administration.
Read more on IMVT →About Nasdaq100 ETF
The ETF is designed to track the performance of the securities and the stocks in the NASDAQ-100 Index. To maintain the composition and weightings, the advisor adjusts the ETF from time to time to conform to periodic changes in the index target.
Read more on QQQ →
